Nextcure Inc(NXTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:00 PM ET (Korea 11/4 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -10.59 | Insider Own | 16.3% | Shs Outstand | 4.1M | Perf Week | 3.41% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 78.23% | Insider Trans | 78.3% | Shs Float | 3.8M | Perf Month | 17.03% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.9 | Inst Own | 48.11% | Short Float | 5.77% | Perf Quarter | 12.57% |
| Income | -0.04B | P/S | - | EPS this Y | 67.74% | Inst Trans | -6.43% | Short Ratio | 1.51 | Perf Half Y | -36.59% |
| Sales | 0.00B | P/B | 1.98 | EPS next 5Y | 60.4% | ROA | -121.6% | Short Interest | 0.22M | Perf YTD | -58.35% |
| Book/sh | 2.99 | P/C | 1.35 | EPS past 3/5Y | 15.29% -4.25% | ROE | -195.22% | 52W High | -62.45% ($15.74) | Perf Year | -50.67% |
| Cash/sh | 4.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | -271.38% | 52W Low | 281.29% ($1.55) | Perf 3Y | -58.26% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 59.14% | Gross Margin | - | Volatility(W/M) | 12.95% 15.56% | Perf 5Y | -94.36% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.47 | EPS Q/Q | 75.16% | Profit Margin | - | RSI (14) | 50.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.47 | Sales Q/Q | - | SMA20 | -2.38% ($6.05) | Beta | 1.21 | Target Price | $20 |
| Payout | - | Debt/Eq | 0.35 | Earnings | 2026/8/6 | SMA50 | -2.9% ($6.09) | Rel Volume | 0.23 | Prev Close | $5.7 |
| Employees | 40 | LT Debt/Eq | 0.3 | EPS/Sales Surpr. | -43.59% - | SMA200 | -24% ($7.78) | Avg Volume(3M) | 0.15M | Price | $5.91 |
| IPO | 2019/5/9 | Option/Short | No/Yes | Trades | 344 | Volume | 33,366 | Change | 3.78% |
🔬 This is a clinical-stage biotech developing antibody-drug conjugates (ADCs) for cancer treatment. Its lead candidates include SIM0505, targeting CDH6, and LNCB74, targeting B7-H4, both currently in clinical trials for ovarian cancer and other solid tumors. The company has yet to generate any product revenue and holds sufficient operating funds through the first half of 2027.
Over the past 1 year, roughly in the middle
62% below its 1-year high.
Traded less than usual. That is 23% of its average volume.
NXTC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.4%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 48.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #450 of 597 in the industry
Based on market cap of $27M.
FAQ
What kind of company is NXTC?
NXTC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NXTC?
The market cap of NXTC is approximately $27M, ranking 5,109 within its sector.
What is the 52-week high and low for NXTC?
NXTC has recorded a 52-week high of $15.74 and a low of $1.55.
